BioWorld

April 5, 2005

Curis' Second Agreement With Genentech Worth Up To $149M

Establishing a second major collaboration, this time in the fields of cancer and tissue repair, Curis Inc. and Genentech Inc. joined forces to discover and develop small-molecule modulators of an undisclosed pathway. (BioWorld Today) Read More

Genzyme Advances Diarrhea Product Into Pivotal Testing

Nuvelo's Secreted Protein Find Leads To Agreement With Kirin

PharmaMar's Yondelis Phase III Trial Started In Ovarian Cancer

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...